SG11202103118PA - Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof - Google Patents
Crystal form of morpholino quinazoline compound, preparation method therefor and use thereofInfo
- Publication number
- SG11202103118PA SG11202103118PA SG11202103118PA SG11202103118PA SG11202103118PA SG 11202103118P A SG11202103118P A SG 11202103118PA SG 11202103118P A SG11202103118P A SG 11202103118PA SG 11202103118P A SG11202103118P A SG 11202103118PA SG 11202103118P A SG11202103118P A SG 11202103118PA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- crystal form
- method therefor
- quinazoline compound
- morpholino quinazoline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811131702 | 2018-09-27 | ||
| PCT/CN2019/105688 WO2020063368A1 (en) | 2018-09-27 | 2019-09-12 | Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103118PA true SG11202103118PA (en) | 2021-04-29 |
Family
ID=69953307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103118PA SG11202103118PA (en) | 2018-09-27 | 2019-09-12 | Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11168072B2 (en) |
| EP (1) | EP3858830B1 (en) |
| JP (1) | JP7071588B2 (en) |
| KR (1) | KR20210069664A (en) |
| CN (1) | CN110950844B (en) |
| AU (1) | AU2019345706B2 (en) |
| BR (1) | BR112021006026A2 (en) |
| CA (1) | CA3114260A1 (en) |
| EA (1) | EA202190880A1 (en) |
| MX (1) | MX2021003576A (en) |
| SG (1) | SG11202103118PA (en) |
| TW (1) | TWI820223B (en) |
| WO (1) | WO2020063368A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202190880A1 (en) | 2018-09-27 | 2021-06-28 | Шанхай Инли Фармасьютикал Ко., Лтд | CRYSTALLINE FORM OF MORPHOLINOQUINAZOLINE COMPOUND, METHOD OF ITS PREPARATION AND ITS APPLICATION |
| WO2022199375A1 (en) * | 2021-03-26 | 2022-09-29 | 上海璎黎药业有限公司 | Pharmaceutical composition of quinazoline compound and preparation method therefor |
| WO2022228218A1 (en) * | 2021-04-30 | 2022-11-03 | 上海璎黎药业有限公司 | Application of quinazoline compound and pharmaceutical composition |
| WO2023030437A1 (en) * | 2021-09-01 | 2023-03-09 | 江苏恒瑞医药股份有限公司 | Use of pi3k inhibitor and btk inhibitor in preparation of drug for treating lymphoma |
| WO2024041519A1 (en) * | 2022-08-24 | 2024-02-29 | 上海璎黎药业有限公司 | Morpholinyl quinazoline compound, and pharmaceutical composition and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101889015B (en) | 2007-10-05 | 2014-06-04 | 维拉斯通股份有限公司 | Pyrimidine substituted purine derivatives |
| WO2009146406A1 (en) | 2008-05-30 | 2009-12-03 | Genentech, Inc. | Purine pi3k inhibitor compounds and methods of use |
| CA2926596C (en) | 2013-10-16 | 2020-07-14 | Shanghai Yingli Pharmaceutical Co., Ltd | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof |
| NZ727185A (en) * | 2014-06-24 | 2018-04-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
| EP3395811B1 (en) * | 2015-12-25 | 2020-05-13 | Xuanzhu Pharma Co., Ltd. | Crystals of quinazoline derivative and preparation method therefor |
| EA202190880A1 (en) | 2018-09-27 | 2021-06-28 | Шанхай Инли Фармасьютикал Ко., Лтд | CRYSTALLINE FORM OF MORPHOLINOQUINAZOLINE COMPOUND, METHOD OF ITS PREPARATION AND ITS APPLICATION |
-
2019
- 2019-09-12 EA EA202190880A patent/EA202190880A1/en unknown
- 2019-09-12 AU AU2019345706A patent/AU2019345706B2/en active Active
- 2019-09-12 SG SG11202103118PA patent/SG11202103118PA/en unknown
- 2019-09-12 CA CA3114260A patent/CA3114260A1/en active Pending
- 2019-09-12 KR KR1020217012398A patent/KR20210069664A/en unknown
- 2019-09-12 JP JP2021516990A patent/JP7071588B2/en active Active
- 2019-09-12 EP EP19864074.0A patent/EP3858830B1/en active Active
- 2019-09-12 US US17/279,185 patent/US11168072B2/en active Active
- 2019-09-12 MX MX2021003576A patent/MX2021003576A/en unknown
- 2019-09-12 CN CN201910861902.7A patent/CN110950844B/en active Active
- 2019-09-12 WO PCT/CN2019/105688 patent/WO2020063368A1/en unknown
- 2019-09-12 BR BR112021006026-0A patent/BR112021006026A2/en unknown
- 2019-09-27 TW TW108135116A patent/TWI820223B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| US11168072B2 (en) | 2021-11-09 |
| EP3858830A1 (en) | 2021-08-04 |
| CN110950844A (en) | 2020-04-03 |
| JP2021528487A (en) | 2021-10-21 |
| BR112021006026A2 (en) | 2021-06-29 |
| MX2021003576A (en) | 2021-05-28 |
| EA202190880A1 (en) | 2021-06-28 |
| KR20210069664A (en) | 2021-06-11 |
| EP3858830A4 (en) | 2021-09-15 |
| US20210317104A1 (en) | 2021-10-14 |
| TWI820223B (en) | 2023-11-01 |
| TW202024066A (en) | 2020-07-01 |
| WO2020063368A1 (en) | 2020-04-02 |
| AU2019345706A1 (en) | 2021-05-27 |
| CA3114260A1 (en) | 2020-04-02 |
| CN110950844B (en) | 2024-01-30 |
| JP7071588B2 (en) | 2022-05-19 |
| AU2019345706B2 (en) | 2024-02-22 |
| EP3858830B1 (en) | 2022-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202103118PA (en) | Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof | |
| ZA202001447B (en) | M-diamide compound and preparation method therefor and use thereof | |
| EP3502113A4 (en) | Pharmaceutically acceptable salt of egfr inhibitor, crystal form thereof, preparation method therefor and application thereof | |
| EP3246328A4 (en) | Quinazoline heterocyclic compound as egfr kinase inhibitor, and preparation and application thereof | |
| EP3470400A4 (en) | Crystal form of ozanimod, crystal form of hydrochloride thereof, and preparation method therefor | |
| EP3269719A4 (en) | Crystal form of jak inhibitor and preparation method thereof | |
| EP3508481A4 (en) | Crystal form of ozanimod hydrochloride, and preparation method therefor | |
| EP3647312A4 (en) | Crystal form of deuterated azd9291, preparation method therefor, and use thereof | |
| EP3269711A4 (en) | Stable apremilast crystal form ii free of solvates, and preparation method therefor | |
| EP3812378A4 (en) | Crystal form of arn-509, preparation method therefor and use thereof | |
| HK1256860A1 (en) | Crystals of quinazoline derivative and preparation method therefor | |
| EP3502100A4 (en) | Crystal forms of ozanimod and preparation method therefor | |
| EP3495352A4 (en) | Crystal form of androgen receptor antagonist medication, preparation method therefor, and use | |
| EP3312151A4 (en) | Oxidation-induced self-healing ceramic composition containing healing activator, method for producing same, use of same, and method for enhancing functionality of oxidation-induced self-healing ceramic composition | |
| EP3941459A4 (en) | Quinoline and quinazoline compounds and methods of use thereof | |
| EP3530650A4 (en) | Crystalline form of (r)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, preparation method therefor and use thereof | |
| EP3369733A4 (en) | Crystal form of 4h-pyrazolo[1,5- ]benzoimidazole compound, preparation method therefor and intermediate thereof | |
| EP3805229C0 (en) | Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof | |
| EP3330267A4 (en) | Salt of quinazoline derivative or crystal thereof, and method for producing salt of quinazoline derivative or crystal thereof | |
| EP3733666A4 (en) | Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof | |
| IL263868A (en) | Crystal form of 9-aminomethyl substituted tetracycline compounds and preparation method therefor | |
| HK1252375A1 (en) | Crystals of quinazoline derivative and preparation method therefor | |
| EP3736273A4 (en) | Novel crystal form of acalabrutinib and preparation method and use thereof | |
| HK1258757A1 (en) | Salt type and crystal type of 4h-pyrazolo[1, 5-alpha]benzimidazole compound and preparation method and intermediate thereof | |
| IL310703A (en) | Crystal form of lanifibranor, preparation method therefor, and use thereof |